These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 26579955)
1. The Psychopharmacology of ±3,4 Methylenedioxymethamphetamine and its Role in the Treatment of Posttraumatic Stress Disorder. Amoroso T J Psychoactive Drugs; 2015; 47(5):337-44. PubMed ID: 26579955 [TBL] [Abstract][Full Text] [Related]
3. Progress and promise for the MDMA drug development program. Feduccia AA; Holland J; Mithoefer MC Psychopharmacology (Berl); 2018 Feb; 235(2):561-571. PubMed ID: 29152674 [TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Mithoefer MC; Wagner MT; Mithoefer AT; Jerome L; Doblin R J Psychopharmacol; 2011 Apr; 25(4):439-52. PubMed ID: 20643699 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials. Yang J; Wang N; Luo W; Gao J Psychiatry Res; 2024 Sep; 339():116043. PubMed ID: 38896930 [TBL] [Abstract][Full Text] [Related]
6. MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. Smith KW; Sicignano DJ; Hernandez AV; White CM J Clin Pharmacol; 2022 Apr; 62(4):463-471. PubMed ID: 34708874 [TBL] [Abstract][Full Text] [Related]
7. MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics". Sessa B Neurosci Lett; 2017 May; 649():176-180. PubMed ID: 27394687 [TBL] [Abstract][Full Text] [Related]
8. Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions. Schenk S; Newcombe D J Clin Psychopharmacol; 2018 Dec; 38(6):632-638. PubMed ID: 30303861 [TBL] [Abstract][Full Text] [Related]
9. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. Amoroso T; Workman M J Psychopharmacol; 2016 Jul; 30(7):595-600. PubMed ID: 27118529 [TBL] [Abstract][Full Text] [Related]
10. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. Johansen PØ; Krebs TS J Psychopharmacol; 2009 Jun; 23(4):389-91. PubMed ID: 19273493 [TBL] [Abstract][Full Text] [Related]
11. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Mithoefer MC; Mithoefer AT; Feduccia AA; Jerome L; Wagner M; Wymer J; Holland J; Hamilton S; Yazar-Klosinski B; Emerson A; Doblin R Lancet Psychiatry; 2018 Jun; 5(6):486-497. PubMed ID: 29728331 [TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Oehen P; Traber R; Widmer V; Schnyder U J Psychopharmacol; 2013 Jan; 27(1):40-52. PubMed ID: 23118021 [TBL] [Abstract][Full Text] [Related]
13. Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder. Zeifman RJ; Kettner H; Ross S; Weiss B; Mithoefer MC; Mithoefer AT; Wagner AC Eur J Psychotraumatol; 2024; 15(1):2297536. PubMed ID: 38174611 [TBL] [Abstract][Full Text] [Related]
14. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review. Parrott AC Psychopharmacology (Berl); 2007 Apr; 191(2):181-93. PubMed ID: 17297639 [TBL] [Abstract][Full Text] [Related]
15. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Feduccia AA; Mithoefer MC Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):221-228. PubMed ID: 29524515 [TBL] [Abstract][Full Text] [Related]
16. Making a medicine out of MDMA. Sessa B; Nutt D Br J Psychiatry; 2015 Jan; 206(1):4-6. PubMed ID: 25561485 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Young MB; Norrholm SD; Khoury LM; Jovanovic T; Rauch SAM; Reiff CM; Dunlop BW; Rothbaum BO; Howell LL Psychopharmacology (Berl); 2017 Oct; 234(19):2883-2895. PubMed ID: 28741031 [TBL] [Abstract][Full Text] [Related]
18. Psychedelic Therapy: A Primer for Primary Care Clinicians-3,4-Methylenedioxy-methamphetamine (MDMA). Shinozuka K; Tabaac BJ; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS Am J Ther; 2024 Mar-Apr 01; 31(2):e141-e154. PubMed ID: 38518271 [TBL] [Abstract][Full Text] [Related]
19. The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns. Baldo BA Arch Toxicol; 2024 Aug; 98(8):2409-2427. PubMed ID: 38743292 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis. Bahji A; Forsyth A; Groll D; Hawken ER Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109735. PubMed ID: 31437480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]